Keywords
mitomycin-c, urethral stricture, internal urethrotomy
mitomycin-c, urethral stricture, internal urethrotomy
In this new version, we added 1 more study. Length of stricture is also removed, since it is not necessary. Stricture recurrence definition has now also been mentioned. Analysis is now conducted by random effect model because of relatively small studies and between studies are quite different.
See the authors' detailed response to the review by Laetitia M. O. de Kort
See the authors' detailed response to the review by Farhad Shokraneh
Urethral stricture often impairs quality of life and may result in a large economic burden1. There are several procedures available for treating this condition, ranging from minimally invasive procedures like internal optical urethrotomy (IOU) to invasive procedure such as urethroplasty, with or without grafting, and tissue engineering2. However, despite the methods available, urethral stricture often recurs. Several manipulations have been tried to prevent urethral stricture, such as indwelling catheter insertion, urethral calibration procedure, and home self-catheterization. Unfortunately, repeated instrumentation can cause scar formation. Moreover, it can also complicate subsequent reconstruction, which can lead to several complications3,4. On the other hand, there have been several studies evaluating the effects of antifibrotic drugs such as glucocorticoid and mitomycin-C on urethral strictures. Mitomycin-C is an agent that has the potential to inhibit mitosis, fibroblast proliferation, formation of blood vessels, and synthesis of protein and collagen. This agent plays role in tissue healing process and scar formation by reducing the release of matrix proteins by inhibiting proliferative fibroblasts5.
To our knowledge, there have not been any systematic reviews or meta-analyses regarding the efficacy of mitomycin-C in treating anterior urethral stricture post internal urethrotomy. Thus, the present study aims to investigate the efficacy of mitomycin-C in treating anterior urethral stricture post internal urethrotomy. We hope that by conducting this review and analysis, a definite conclusion regarding the efficacy of such treatment could be achieved.
This systematic review was conducted based on guidelines from the Oxford University Center for Evidence-Based Medicine6. Our present study aims to determine whether mitomycin-C provide better efficacy compared to controls (without mitomycin-C) in adult patients with anterior urethral stricture after internal urethrotomy.
To be considered for inclusion, the included studies were required to be randomized controlled trials (RCTs) study investigating efficacy of mitomycin-C as the additional treatment to internal urethrotomy in anterior urethral stricture. We expanded the searching by including related studies suggested by the databases. Year of publishing was not considered as inclusion criterion. Any study until March 15th 2020 was included. The primary outcome measures were efficacy of mitomycin-C administration, determined by risk ratio for proportion results and mean difference for continuous data. Animal studies, case series, case report, editorials, and book chapters were excluded.
To find suitable studies to be included in this review, we used PubMed, Scopus, ScienceDirect, MEDLINE, and Cochrane Reviews as directory databases. We used combination of keywords “((((((mitomycin c[MeSH Terms]) OR mitomycin[MeSH Terms]) OR mitomycin c)) AND ((((((((((((((((urethral stricture[MeSH Terms]) OR urethral strictures[MeSH Terms]) OR stricture, urethral[MeSH Terms]) OR strictures, urethral[MeSH Terms]) OR urethral stenosis[MeSH Terms]) OR urethral stenoses[MeSH Terms]) OR stenosis, urethral[MeSH Terms]) OR stenoses, urethral[MeSH Terms]) OR urethral stricture) OR urethral strictures) OR stricture, urethral) OR strictures, urethral) OR urethral stenosis) OR urethral stenoses) OR stenosis, urethral) OR stenoses, urethral)) AND “urethra/surgery”[MeSH Terms]) AND Humans[Mesh]”. We also used term “human” as limiting term to exclude every study that was not conducted on human subjects.
We evaluated the study using appraisal worksheet for randomized clinical trial from Oxford University Center for Evidence-Based Medicine to stratify the risk of bias6. Using Revman 5.3 software, recurrence number from all selected studies were analyzed. Data were analyzed using forest plots with calculation of random effect. It was also done using Revman 5.3 to show relative risk/risk ratio for recurrence rate variable dan p-value. We summarized the conclusion of each study at the table along with its appraisal. We decided to use random effect model since the small amount of study and the difference between them.
Searching process (searching strategy showed in Figure 1) by using six databases found 49 study articles. There were 29 articles eliminated after title and abstract screening. The remained 20 articles were reduced to six articles after eliminating duplicates, leaving seven full text articles to be reviewed. Based on study design, we eliminated three articles, leaving four articles to be summarized in systematic review and meta-analysis.
Four selected studies were conducted in 2007, 2015, 2016, and 20192,4,7,8. All studies evaluated the effectivity of mitomycin-C given after internal urethrotomy for anterior urethral stricture. From these selected articles, three evaluated the usage of submucosal injection of mitomycin-C for anterior urethral stricture after urethrotomy. How mitomycin-C was injected differed in every study. Mazdak et al.4 study used 0,1 mg of Mitomycin-C in 2 ml of distilled water injected in four quadrants, Ali et al.2 study used 0,1% Mitomycin-C injected in three quadrants, and Islam et al.7 study used 0,1 mg in 2 ml of distilled water in two quadrants. Moradi et al.8 study evaluated intraluminal injection of Mitomycin-C in hydrogel base, consisting of 0.8 mg Mitomycin-C with 1cc water and propylene glycol to PF-127 poloxamer. The hydrogel base was injected through a small feeding tube to reach the site of stricture. All studies applied mitomycin-C after internal urethrotomy procedure and were conducted in populations with different age means. Each of studies’ quality was assessed using guide from Oxford University Center for Evidence-Based Medicine; this is explained in Table 1 and Table 2.
Studies | Average age (year) | Pre-intervention stricture site | Procedure of internal urethrotomy | Clinical feature | Cause of injury | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
MMC group | Control group | MMC Group | Control group | Urinary retention | Bladder Outlet Obstruction | Azotemia | Urosepsis | Mitomycin-C Group | Control group | ||
Moradi et al., 20168 | 54.55 ± 21.25 | 53.75 ± 24.75 | Anterior urethral stricture | Trans-urethral incision at 12 o’clock via cold knife urethrotomy | N/A | N/A | |||||
Ali et al., 20152 | 37.31 ± 10.1 | 40.1 ± 11.4 | Bulbar urethra: 84.6% Penile urethra: 15.4% | Bulbar urethra: 78.1% Penile urethra: 21.9% | Internal Optic urethrotomy | Mitomycin-C group | Road traffic: 59% Iatrogenic: 30.8% Straddle: 9% Infective: 1.3% | Road traffic: 71.2% Iatrogenic: 21.9% Straddle: 6.8% Infective: - | |||
70.5% | 16.6% | 10.2% | 2.5% | ||||||||
Control group | |||||||||||
57.5% | 31.5% | 9.5% | 1.3% | ||||||||
Mazdak et al., 20074 | 29.8 (15– 70) | 29.2 (11–66) | Anterior urethral stricture | Trans- urethral incision at 12 o’clock via cold knife urethrotomy | N/A | Straddle injury or other blunt perineal trauma | |||||
Islam et al., 20197 | 49.43 ± 8.10 | 48.98±7.20 | Anterior urethral stricture | Internal Optic Urethrotomy | N/A | Idiopathic, lichen sclerosus, urethritis, or unknown |
Studies | LoE | Sample size | Methods of mitomycin- C application | Timing of mitomycin- C application | Follow up end- point | Validity | Importance | Applicability | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Randomized allocation | Similarity of group | Equal Treatment | Minimal Loss to Follow- up | Blinding | Relevance | Feasibility | Benefit Overweight the Harm | |||||||||
Moradi et al., 20168 | 1b | 40 | Intraluminal injection of 0.8 mg mitomycin-C + propylene glycol through indwelling catheter | After Internal Urethrotomy | 12 months | Not stated | Yes | Yes | Yes | Not stated | RR = 0.20 ARR = 0.40 RRR = 0.80 NNT = 2.5 | Unsure | Yes | Yes | ||
Ali et al., 20152 | 1b | 180 | Submucosal injection of 0.1% mitomycin- C at three quadrants (1, 11, & 12 o’clock position) using TLA needle | After Internal Urethrotomy | 18 months | Yes | No | Yes | Yes | Not stated | RR = 0.38 ARR = 0.23 RRR = 0.62 NNT = 4.35 | Unsure | Yes | Yes | ||
Mazdak et al., 20074 | 1b | 40 | Submucosal injection of 0.1 mg mitomycin- C in four quadrants (1,5,7, & 11 o’clock position) using 22- Gauze cystoscopic needle | Before Internal Urethrotomy | 6 months | Not stated | Yes | Yes | Yes | Not stated | RR = 0.20 ARR = 0.40 RRR = 0.80 NNT = 2.5 | Unsure | Yes | Yes | ||
Islam et al., 20197 | 1b | 80 | Submucosal injection of 0.1 mg Mitomycin- C in two quadrants (11 & 1 o’clock) using 21-gauge cystoscopic needle | After internal Urethrotomy | 6 months | Yes | Yes | Yes | Yes | Not stated | RR = 0.62 ARR = 0.25 RRR = 0.38 NNT = 4 | Unsure | Yes | Yes |
We included the studies in which recurrence was defined by a patient having obstructive symptoms, obvious stricture at retrograde urethrography, or uroflowmetry with maximum flow rate less than 12 mL/s, and stricture was measured using retrograde urethrogram or ultrasonography of the urethra. The outcome that measured was recurrence rate (percentage).
All selected articles stated that Mitomycin-C had a significant effect on preventing or delaying urethral stricture recurrence post internal urethrotomy. All studies reported that the time-based recurrence rates in the two groups differed, where lower recurrence rates were found in the group given Mitomycin-C2,4,7,8. From study characteristic that is quite different and small number of studies, we choose to use random-effect model in forest plot showed in Figure 2. This forest plot suggests that there were significant differences between cases and control group. It showed from risk ratio is 0.41 with 95% confidence interval of 0.25 until 0.68, with p value <0.05.
Urethral stricture is a serious complication in male patients, which causes great morbidity and considerable health-related costs. This condition often results in voiding dysfunction, which will affect quality of life. Moreover, this voiding disfunction can trigger chain of events leading to renal failure. Majority of the recommended treatment methods have low success rate9. A recent survey revealed that 86% of American urologists prefer internal urethrotomy when treating anterior urethral stricture10. However, internal urethrotomy is associated with a high rate of urethral stricture recurrence, ranging from 20 to 60%11,12. Although several methods have been introduced to lower recurrence rate, including clean intermittent self-catheterization13, numerous authors has labeled this a failure as it could not fully prevent recurrence of urethral stricture.
Despite unclear pathophysiology of urethral stricture, a pathophysiological mechanism suggested is fibrosis caused by excessive synthesis of collagen and altered extracellular matrix14,15. Therefore, any drug or procedure which can delay fibrosis after internal urethrotomy would lead to an increase of surgical success rates and patient comfort, and therefore decrease treatment costs. Therefore, many studies have been performed to explore different molecules the can prevent fibrosis and urethral stricture recurrence4,14–17.
Mitomycin-C is an alkylating antineoplastic antibiotic, produced by Streptomyces caespitosus. Mitomycin-C can inhibit DNA synthesis by linking adenine and guanine, resulting in DNA cross-linking. It can suppress cellular RNA and protein synthesis, and is not cell cycle specific9. Therefore, it can delay the healing process by preventing replication of fibroblasts and epithelial cells, as well as inhibiting collagen synthesis18. It has been shown that mitomycin-C can improve the success rates of trabeculotomy and myringotomy by preventing proliferation of fibroblasts and development of fibrosis19,20.
The anti-fibroblast activity mechanism of mitomycin-C is unknown. Experts have suggested that the reduction of fibroblast activity may be mediated by myofibroblasts apoptosis2,4,12. As the wound closes, apoptosis of myofibroblast and vascular cells increases, indicating that this is the mechanism by which granulation tissue will lead to scarring21,22.
All the studies included in this review treated the two groups equally and had relatively small loss-to-follow-up rates. A common problem with all the studies included in this review is that there was no clear blinding statement. Mazdak et al.4 and Moradi et al.8 study stated that their studies are randomized. But, the randomization procedure was not stated in the study method. On the other hand, although Ali et al.2 had randomized its subjects, age characteristics in the two groups were significantly different. Every stricture in this review is all primary stricture2,4,7,8.
All studies support the use of mitomycin-C to prevent or delay anterior urethral stricture after internal urethrotomy. This was confirmed by a less rate of recurrence rate in Mitomycin-C patients2,4,8; we found that those who had Mitomycin-C administered had lower incidence of recurrence during one year and 18 months of follow up (RR = 0.32, P < 0.001). This was also confirmed by a series of cases by Farrell et al.,23 Farrell et al.,24 and Sourial et al.25 Mazdak et al.4 injected mitomycin-C into the urethral submucosa and reported that patients with mitomycin-C injection had lower rates of stricture recurrence. Opposing this study, some researchers proposed that submucosal injection could increase the complication rate and reduce the duration of the effective dose within the tissue, which yielded a scientific discussion19. Ayyildiz et al.26 assessed the efficacy of Mitomycin-C for preventing urethral scar by applying the agent topically to the traumatized region in rats. They concluded that mitomycin-C applied locally reduced fibrosis significantly in a dose-independent manner.
Although all studies support the use of Mitomycin-C to prevent or delay post urethrotomy urethral stricture and the side effects reported in the studies reviewed are minimal, in Ali et al.2 and Moradi et al.8 are insignificant, but Mazdak et al.4 and islam et al.7 didn’t asses any side effects, the results of this review need to be followed up with caution. The limitation of this study can be seen from only a few studies that discuss this topic. Some of the existing studies are not enough to be generalized to a wider population, given that selected studies were carried out in Iran and Pakistan2,4,7,8. Therefore their application needs to be carried out wisely and cautiously. Research related to this in the future can still be done with different populations.
Due to short period of follow up time in all studies, some authors2,4 concluded that the study of Mitomycin-C needed firm results regarding long term success. Mazdak et al.4 added that stricture may recur within two years after internal urethrotomy.
Mitomycin-C could be used as a potential additional treatment for anterior urethral strictures after internal urethrotomy. However, further studies are required to investigate the safety and efficacy of this method for treating anterior urethral strictures, as only a limited number of studies presently exist.
All data underlying the results are available as part of the article and no additional source data are required.
Open Science Framework: PRISMA checklist for ‘Efficacy of mitomycin-C on anterior urethral stricture after internal urethrotomy: A systematic review and meta-analysis’. https://doi.org/10.17605/OSF.IO/APU9B27.
The updated PRISMA checklist is available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Evidence Synthesis, Systematic Review, Information Retrieval, Automation of Systematic Reviews, Living Evidence, Scoping Review, Cochrane Review, Database, Clinical Practice Guideline, Overview, Rapid Review, Randomized Controlled Trial, Open Data, Medical Journalism, Outcome, Intervention, Cochrane.
Competing Interests: No competing interests were disclosed.
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
No
Is the statistical analysis and its interpretation appropriate?
Partly
Are the conclusions drawn adequately supported by the results presented in the review?
No
References
1. Azzawi I: [15] The role of mitomycin C intralesional injection during visual internal urethrotomy in urethral stricture recurrence. Arab Journal of Urology. 2018; 16 (sup1): S8-S9 Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Evidence Synthesis, Systematic Review, Information Retireval, Automation of Systematic Reviews, Living Evidence, Scoping Review, Cochrane Review, Database, Clinical Practice Guideline, Overview, Rapid Review, Randomized Controlled Trial, Open Data, Medical Journalism, Outcome, Intervention, Cochrane.
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Partly
Is the statistical analysis and its interpretation appropriate?
Yes
Are the conclusions drawn adequately supported by the results presented in the review?
Partly
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 3 (revision) 10 Aug 20 |
read | read | |
Version 2 (revision) 03 Jun 20 |
read | read | |
Version 1 08 Aug 19 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)